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OBJECTIVES We sought to determine the prevalence of pulmonary artery thrombosis in patients with
Eisenmenger syndrome and to identify individuals at highest risk.
BACKGROUND Eisenmenger syndrome is associated with pulmonary arterial thrombus formation. Both the
prevalence and the determinants of pulmonary arterial thrombosis are unknown.
METHODS This is a review of patients with Eisenmenger syndrome seen at the Toronto Congenital
Cardiac Centre for Adults, Canada. Patients underwent a contrast-enhanced computed
tomographic (CT) scan of the thorax.
RESULTS Forty-nine consecutive patients with Eisenmenger syndrome were seen in our hospital.
Fifteen patients did not undergo CT angiograms; therefore, 34 patients (mean age 42  10
years) were included in the study. Responsible shunts included ventricular septal defect (65%),
atrial septal defect (15%), patent ductus arteriosus (9%), and other (11%). The prevalence of
proximal pulmonary artery thrombus was 21% (7/34) of patients. Evidence of more distal
vessel thrombosis was observed in 43% (3/7) of the patients who had visible thrombus in the
proximal pulmonary arteries. Patients with thrombus were more likely to be female (86% vs.
37%, p  0.04) and to have lower oxygen saturations (72%  9% vs. 85%  6%, p  0.01).
Differences in functional status did not identify patients at highest risk for thrombosis.
CONCLUSIONS Patients with Eisenmenger syndrome have a substantial risk of pulmonary artery thrombus
formation. Women and patients with lower oxygen saturations are at the highest risk of
developing thrombosis. In the context of an increased bleeding tendency in these patients, the
role of anticoagulation treatment needs to be determined. (J Am Coll Cardiol 2003;42:
1982–7) © 2003 by the American College of Cardiology Foundation
Eisenmenger syndrome, a form of cyanotic congenital heart
disease, occurs when original left-to-right shunts increase
pulmonary blood flow and pressure. This results in pulmo-
nary vascular disease and right-to-left or bi-directional
shunting through the original shunt lesions (1). For patients
with Eisenmenger syndrome, conventional medical treat-
ment focuses primarily on avoiding complications. By com-
parison, patients with primary pulmonary hypertension,
where intravascular thrombosis is thought to contribute to
progression of the disease, are routinely anticoagulated to
improve survival (2,3). The value of anticoagulation in
patients with Eisenmenger syndrome has not been estab-
lished. Indeed, Eisenmenger syndrome has been associated
with both bleeding and clotting tendencies (4–9). This
paradox makes recommendations regarding anticoagulation
in these patients difficult. Although bleeding events are
usually mild, more severe events can occur from pulmonary
vascular disease with pulmonary hemorrhage or rupture of
aneurysmal pulmonary arteries (5–10). Hemostatic mecha-
nisms that contribute to bleeding include thrombocyto-
penia, abnormal platelet function, clotting factor deficien-
cies, and depletion of von Willebrand factor (11–15). For
these reasons, avoidance of aspirin, heparin, and coumadin
in these patients has been advocated by many centers.
Paradoxically, these patients are also prone to thrombus
such as laminated thrombus in the proximal pulmonary
arteries, spontaneous in situ thrombosis, and thrombosis in
distal peripheral vessels (4–9). The mechanisms contribut-
ing to thrombus formation are poorly understood. Structural
changes in the vessels, damage to the endothelium with
activation of procoagulants, and impairment in the fibrino-
lytic system are mechanisms that may contribute to throm-
bus formation in these individuals (16–20).
Because of the potential for significant adverse effects
from pulmonary thromboembolic disease in patients with
Eisenmenger syndrome, computed tomographic (CT) an-
giograms have become a component of routine follow-up at
our center. In this study, we sought to determine the
prevalence of pulmonary thrombosis and to identify indi-
viduals at highest risk for thrombosis.
METHODS
Study design. This is a review of patients with Eisen-
menger syndrome seen at the Toronto Congenital Cardiac
Centre for Adults, Toronto, Canada, from February 2001 to
December 2002. All patients with Eisenmenger syndrome
seen for routine clinical follow-up or admitted to the
Toronto General Hospital during the study period were
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included. Eisenmenger syndrome was defined as cyanotic
heart disease resulting from pulmonary hypertension sec-
ondary to reversal or bi-directional shunting across large
intracardiac lesions. All patients who had not had a CT
angiogram within two years before their clinic visit were
scheduled to undergo a contrast-enhanced CT angiogram as
part of their clinical assessment. Patients who did not have
a CT angiogram were not included in the study. The study
was approved by the institutional ethics review board. All
patients signed an informed consent form before the CT
angiogram.
Baseline data collection. Patients underwent history,
physical exam, complete blood count with iron indices,
international normalized ratio (INR) measurement, and a
contrast-enhanced CT angiogram. Baseline clinical data
were collected at the time of the CT scan. Baseline clinical
data included age, gender, underlying cardiac anatomy,
history of bleeding tendencies (e.g., gingival bleeding, epi-
staxis, pulmonary hemorrhage), history of previous throm-
botic events (deep vein thrombosis, pulmonary embolus,
stroke), family history of thrombotic events, history of
pulmonary disease, and the use of anticoagulants or anti-
platelet medication. Functional status was graded according
to the New York Heart Association (NYHA) functional
classification. All patients underwent a standard clinical
examination, including oxygen saturation determined by
oximetry after at least 5 min of rest. A complete blood count
and INR were performed at the time of the clinical visit.
Cardiac imaging. Transthoracic echocardiograms were
performed to verify the underlying anatomical diagnosis,
assess the ventricular function, and determine the right
ventricular systolic pressures when appropriate. Ventricular
function was assessed visually (21). Right ventricular systolic
pressures were determined by previously described methods
using the peak tricuspid regurgitant velocity (22).
All patients underwent CT angiography of the pulmo-
nary arteries using an air-filtered intravenous (IV) line to
protect against paradoxical air bubble emboli. Nonionic
iodinated contrast material (Omnipaque 300 [iohexol],
Nycomed, New York, New York) was administered into a
peripheral vein of the arm, using a power injector at a rate
of 5 ml/s and a mean total dose of 90 ml. High-resolution
CT scans were performed with a Lightspeed QXi scanner
(General Electric Medical Systems, Milwaukee, Wisconsin)
using 1.25-mm collimation. The CT images were used to
measure the diameter of the main pulmonary artery and to
identify thromboses, aneurysms, and mural calcification of
the pulmonary arteries. Measurements of the main pulmo-
nary artery were performed in the transverse plane at the
level of the pulmonary artery bifurcation. Previously de-
scribed criteria were used to detect pulmonary thromboem-
bolism (23). Ventilation-perfusion scans were not per-
formed as part of the protocol.
Statistical analysis. Statistical analysis was performed us-
ing the SPSS package (10.1 Chicago, Illinois). Data are
presented as a mean  SD. Comparisons between categor-
ical variables (gender, history of bleeding or thrombosis,
functional class, calcification in the pulmonary arteries, and
right ventricular dysfunction) in patients with and without
pulmonary thrombus were performed using the Fisher exact
test. Comparisons between continuous variables (age, body
mass index, baseline oxygen saturations, size of main pul-
monary arteries, right ventricular systolic pressure, hemo-
globin levels, mean corpuscular volume, and platelet count)
in patients with and without pulmonary thrombus were
performed using the Student t test. The test determined the
relationship between gender and baseline oxygen satura-
tions. Statistical significance was set at a p value of 0.05
(two-sided).
RESULTS
Forty-nine patients with Eisenmenger syndrome were seen
in our hospital during the study period. Fifteen patients did
not undergo CT angiography, therefore, 34 patients are
included in this study. Baseline characteristics are presented
in Table 1. The mean age of the population was 41  10
years. The majority of patients had ventricular septal defects
(65%) as the cause of their Eisenmenger syndrome, followed
by atrial septal defects (15%) and patent ductus arteriosus
(9%). Four patients had histories of thrombotic events: two
patients with pulmonary thrombus and two with cerebro-
vascular events. Mean baseline oxygen saturations and
hemoglobin levels were 82  9% and 188  28 g/l,
respectively. The mean INR was 1.4  0.5 IU. Fifteen
percent of patients were on anticoagulants at the time of the
clinical visit.
Of the 15 patients who did not undergo CT angiograms,
7 had ventricular septal defects, 6 had atrioventricular septal
defects, and 2 had atrial septal defects (Table 1). Patients
who did not undergo CT angiography were more likely to
have atrioventricular septal defects compared to the study
group. All patients with atrioventricular septal defects had
Down syndrome. Reasons for exclusion included reluctance
of patients to undergo additional testing or IV insertion,
inability to consent for the CT scan, medical instability,
iodine allergy, and renal insufficiency.
Pulmonary artery thrombus. The prevalence of proximal
pulmonary artery thrombus was 21% (7/34) of patients.
Anatomical diagnosis of patients with pulmonary thrombus
included three ventricular septal defects, one multiple mus-
cular ventricular septal defect, one atrial septal defect, one
unrepaired patent ductus arteriosus, and one patient with
univentricular anatomy. Of the seven patients with pulmo-
nary thrombus, all had thrombus involving the main pul-
Abbreviations and Acronyms
CT  computed tomography/tomographic
INR  international normalized ratio
NYHA  New York Heart Association
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monary artery segments. Patients had enlargement of the
pulmonary arteries ranging from 37 to 77 mm (Fig. 1).
Evidence of more distal vessel thrombosis was observed in
43% (3/7) of the patients who had a visible thrombus in the
proximal pulmonary arteries (Fig. 2A and B).
Clinically, two patients were stable and the thrombus was
detected during routine screening at the time of their annual
clinical visit. In two other patients, pulmonary thrombus
had been previously reported; one patient was on antico-
agulants. Both patients had CT scans during the study
period, which showed dilated pulmonary arteries and per-
sistent chronic laminated thrombus. Of these two patients,
one died suddenly in her sleep during the study period. The
other patient, who had been deteriorating clinically, under-
went heart-lung transplant and died on the first postoper-
ative day. The remaining three patients presented to our
hospital with clinical deterioration (one with seizures and
two with functional deterioration) requiring hospital admis-
sion.
Prior to the diagnosis of pulmonary thrombus, one
patient was on an antiplatelet agent after a cerebral throm-
botic event. No patients were on anticoagulants before the
diagnosis of pulmonary thrombus. None of the women with
documented thrombus were taking oral contraceptive pills
or hormone replacement therapy at the time of the clinical
visit.
Table 1. Baseline Characteristics
Included Patients
(n  34)
Excluded Patients
(n  15)
Patient characteristics
Age (yrs) 41  10 41  15
Female gender 16 (47%) 11 (73%)
Cardiac diagnosis
Ventricular septal defect 22 7
Atrial septal defect 5 2
Atrioventricular septal defect 1 6
Patent ductus arteriosus 3 0
Univentricular heart 2 0
Other 2 0
Oxygen saturations (% saturation) 82  9 86  6
NYHA functional class III 10 (31%) 3 (20%)
History of bleeding 12 (35%) 3 (20%)
History of thrombotic events 4 (11%) 0
Use of anticoagulants 5 (15%) 1 (7%)
Use of antiplatelets 3 (9%) 1 (7%)
Echocardiography/computed tomography
Right ventricular dysfunction 19 (56%) 6 (40%)
Right ventricular systolic pressure (mm Hg)
(n  25)
97  34 94  22
Size of the main pulmonary artery (mm) 44  10 N/A
Calcified pulmonary artery 10 (29%) N/A
Hematology
Hemoglobin (g/l) 188  28 181  31
Mean corpuscular volume (fl) 92  9 101  37
Platelets (109/l) 157  62 152  85
International normalized ratio (IU) (n  20) 1.4  0.5 N/A
N/A  data are not available; NYHA  New York Heart Association.
Figure 1. Axial computed tomography angiography image at the level of the
main pulmonary artery bifurcation shows dilation of the main pulmonary
arteries and an eccentric 23-mm mural thrombus along the posterior wall of
the right pulmonary artery. The thrombus is composed of multiple layers of
thrombus with embedded linear calcifications suggesting repeated events
during formation. Calcifications are also seen along the anterior free wall of the
right pulmonary artery and its main branches (long arrows) and in the left
interlobar artery (short arrow). Ao  ascending aorta; MPA  main
pulmonary artery.
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Comparison between patients with and without throm-
bus. Difference in baseline characteristics among patients
with and without pulmonary thrombus are shown in Table
2. Compared with patients who did not have evidence of
pulmonary thrombus, patients with thrombus were more likely
to be female (86% vs. 37%, p  0.04) and have lower oxygen
saturations (72  9% vs. 85  6%, p  0.01). A statistically
significant relationship was observed between gender and
oxygen saturations (males 85 6% vs. females 79 10%, p
0.02). Clinically, we did not observe a difference in baseline
NYHA functional status or prevalence of admissions for
clinical deterioration between patients with and without pul-
monary thrombus. Body mass index was similar in patients
with and without pulmonary thrombus. Baseline hemoglobin
levels, mean corpuscular volume, and platelet counts were not
statistically different in patients with and without thrombus.
Although not statistically significant, a history of bleeding
(57% vs. 30%, p  0.21) and thrombotic events (29% vs. 7%,
p  0.18) was more commonly observed in patients with
pulmonary thrombus. Anatomical differences in the size of the
main pulmonary artery between patients with and without
thrombus were not observed (47  15 mm vs. 43  9 mm,
p  0.52); however, patients with pulmonary thrombus were
more likely to have calcification in the pulmonary arteries (71%
vs. 19%, p 0.01). Calcifications were typically found embed-
ded in the laminated thrombus. No difference was seen in the
right ventricular systolic pressure (113  31 mm Hg vs. 99 
32 mm Hg, p  0.47) or the presence of right ventricular
dysfunction (71% vs. 56%, p 0.63) between the two groups.
DISCUSSION
This is the first study to document the prevalence and the
determinants of pulmonary thrombus in patients with
Eisenmenger syndrome. We have shown a 21% prevalence
of pulmonary artery thrombus in this cohort of patients.
Forty-three percent of the patients with proximal thrombus
also had evidence of more distal vessel thrombosis. The
frequent finding of calcification within the laminated
thrombus suggests a chronic thrombotic lesion. Thrombus
was more likely to develop in women and in patients with
lower systemic arterial oxygen saturation.
Mechanisms of pulmonary thrombosis. Structural and
functional changes in the pulmonary artery wall likely
contribute to the thrombotic disease that develops in pa-
tients with Eisenmenger syndrome. Although the charac-
teristic structural changes of pulmonary hypertension occur
in the neomuscularized small arteries, changes also occur in
larger vessels. The large arteries may dilate and become
aneurysmal (9,10). These changes can contribute to stasis
and mural thrombus formation. In addition, injured endo-
thelium, which plays a critical role in the vascular changes
occurring during the development of primary pulmonary
hypertension, may also contribute to thrombus formation in
this group of patients. Endothelium can be damaged by the
increased shear stress on the vessel walls, by increased blood
viscosity, and by chronic hypoxemia (24). In patients with
primary pulmonary hypertension, the damaged endothelium
leads to a thrombotic state with decreased fibrinolytic
activity and release of procoagulant factors (16–20). Similar
mechanisms are likely involved in the thrombus formation
in patients with other forms of pulmonary hypertension
such as Eisenmenger syndrome. Prognostically, markers of
endothelial cell dysfunction have been associated with worse
short-term survival in patients with pulmonary hypertension
Figure 2. (A) Axial computed tomography angiography image at the level
of the main pulmonary arteries demonstrates severe dilation, with the main
pulmonary artery measuring 71 mm. There is an associated eccentric
irregular thrombus in the left main pulmonary artery (short arrows). A tiny
focus of calcification is noted in the posterior wall of the right pulmonary
artery (long arrow). (B) Axial image at the level of lung bases showing
extension of the thrombus into the segmental basal arteries of the left lower
lobe (short arrows).
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(25). We did not measure markers of endothelial dysfunc-
tion in this study. We found that lower oxygen saturations
were associated with the presence of pulmonary arterial
thrombosis. Poor oxygen saturations likely reflect larger
intracardiac right-to-left shunting, lower pulmonary blood
flow, more advanced disease, and, in turn, potentially worse
endothelial injury.
No studies have examined the predictors of pulmonary
thrombus formation in patients with Eisenmenger syn-
drome. However, in patients with pulmonary embolus, the
Prospective Investigation of the Pulmonary Embolism Di-
agnosis study demonstrated that men were at higher risk of
developing pulmonary emboli compared with women (26).
By comparison, we found that women with Eisenmenger
syndrome were more likely to develop pulmonary thrombo-
sis compared with men. This finding can be at least partially
explained by the observation that, in our series, women had
lower oxygen saturations when compared with men. Be-
cause of the retrospective nature of this study, it is difficult
to determine the sequence of events leading to pulmonary
thrombosis. The reason why women have lower oxygen
saturation and the mechanisms by which these two factors
interact require further study.
Other known risk factors for the development of venous
thromboembolism include obesity and a history of cigarette
smoking. In women, the use of oral contraceptives and hor-
mone replacement therapy confer an additional risk (27–29).
In our study none of the women with pulmonary thrombus
were on oral contraceptive pills or hormone replacement
therapy at the time of the clinical visit, and none of the
patients had a history of cigarette smoking. No difference in
body mass index was observed between patients with and
without pulmonary thrombus.
Finally, we found that pulmonary artery calcification was
seen more frequently in patients with pulmonary thrombo-
sis. The calcium, typically embedded in the laminated
pulmonary artery thrombus, represents the chronic nature of
the thrombus. This feature raises the importance of endo-
thelial damage in the development if in situ thrombosis.
Indeed, the source of the thrombosis in these patients was
not systematically evaluated. Clearly, the etiology, progres-
sion, and ultimately the clinical importance of these pulmo-
nary arterial thromboses needs to be explored.
Clinical implications. The clinical status of the patients
found to have CT evidence of pulmonary thrombus was
variable. Although a proportion of the cases of thrombus
were found during routine screening, others presented with
marked functional deterioration. Because we were unable to
clinically identify patients with thrombus, routine screening
of patients should be considered.
The presence of more distal thrombosis in several of these
patients raises the concern that the pulmonary arterial
thrombosis may be contributing to progression of the
patients’ pulmonary vascular disease through progressive
loss of their pulmonary vasculature. The use of anticoagu-
lation in these patients also needs to be revisited. In patients
without intracardiac lesions, long-term anticoagulation with
coumadin is the treatment of choice for individuals who
develop pulmonary thromboembolism (30,31). Further-
more, because of the presence of microvascular thrombosis
and the tendency for both endothelial and clotting abnor-
malities in patients with primary pulmonary arterial hyper-
tension, long-term prophylactic anticoagulation is also rec-
ommended and is believed to confer a long-term survival
benefit (2,3). However, because of the bleeding risk in
patients with Eisenmenger syndrome and the difficulty
regulating the INR in cyanotic patients, many consider
long-term anticoagulation unsafe. Currently, decisions re-
garding the use of anticoagulation need to be weighed
against the risk of bleeding in any individual patient and the
chronic nature of many of the thrombotic lesions. In view of
the high prevalence of pulmonary thromboembolic disease
and its potential detrimental role to the already abnormal
pulmonary vascular bed, a clinical trial to determine the role
of anticoagulation in patients with Eisenmenger syndrome
would be welcome.
Table 2. Comparisons Between Patients With and Without Thrombus
Thrombus
Present
(n  7)
No Thrombus
Present
(n  27) p Value
Age (yrs) 43  9 41  11 0.72
Female gender 6 (86%) 10 (37%) 0.04
Body mass index (m/kg2) 19  4 22  3 0.14
History of bleeding 4 (57%) 8 (30%) 0.21
History of thromboembolic events 2 (29%) 2 (7%) 0.18
Baseline oxygen saturations (% saturation) 72  9 85  6 0.01
NYHA functional class III 3 (43%) 7 (26%) 0.35
Size of the main pulmonary artery (mm) 47  15 43  9 0.52
Calcified pulmonary artery 5 (71%) 5 (19%) 0.01
Right ventricular systolic pressure (n  25) 113  31 99  32 0.47
Right ventricular dysfunction 5 (71%) 15 (56%) 0.63
Hemoglobin (g/l) 196  23 186  29 0.34
Mean corpuscular volume (fl) 89  11 92  8 0.48
Platelet count (109/l) 137  56 163  64 0.31
NYHA  New York Heart Association.
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Finally, recent data have demonstrated that bosentan, an
endothelin-receptor antagonist, can attenuate the damage
caused by overcirculation-induced pulmonary hypertension
in animal models (32). Whether an endothelin-receptor
antagonist or other vasodilators will prevent damage to the
pulmonary endothelium in humans and act as an inhibitor
of thrombus formation is unknown.
Study limitations. In this study we were unable to include
all patients presenting to our hospital with Eisenmenger
syndrome. However, apart from a higher prevalence of
males and a larger proportion of patients with atrioventric-
ular septal defects who refused to enter the study, clinical
characteristics were similar to the group of patients who
were included. Although low oxygen saturations were asso-
ciated with pulmonary thrombosis, this association does not
imply a cause-and-effect relationship. The mechanism by
which thrombus formation develops is unknown. We did
not routinely perform tests for coagulopathies other than
those described in the Methods section or for other hyper-
coagulable states. Therefore, we cannot comment on the
potential role of coagulopathies as a mechanism of throm-
bosis formation. Ventilation-perfusion scans were not per-
formed as part of this study; therefore, it is possible that we
did not detect more peripheral emboli.
Conclusions. Patients with Eisenmenger syndrome have a
high prevalence of pulmonary arterial thrombotic disease.
Women and patients with lower oxygen saturations are at
highest risk of developing thrombosis. In the context of an
increased bleeding tendency in these patients, the role of
anticoagulation treatment in this population needs to be
determined.
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